Welcome to our dedicated page for Cigna Group SEC filings (Ticker: CI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cigna Group (NYSE: CI) files a broad range of documents with the U.S. Securities and Exchange Commission that together provide a detailed view of its operations as a global health company. These SEC filings cover its activities across Cigna Healthcare and Evernorth Health Services, including health insurance, pharmacy benefit services, specialty pharmacy, care services, and related health solutions.
On this page, you can review current and historical 10-K and 10-Q reports to understand how The Cigna Group describes its business segments, risk factors, and financial performance over time. These filings typically break out results for Evernorth Health Services, Cigna Healthcare, and Corporate and Other Operations, and they explain non-GAAP measures such as adjusted income from operations that management uses to evaluate underlying trends.
The Cigna Group also submits frequent Form 8-K reports. Recent examples include 8-K filings announcing quarterly earnings results, affirmations of full-year outlook, changes to Board committee structures, Board appointments and retirements, and the issuance of senior notes with details on interest rates, maturities, and intended use of proceeds. These current reports highlight material events such as capital markets transactions and governance changes.
Debt offerings and related agreements are documented through exhibits to 8-K filings, including underwriting agreements, supplemental indentures, and legal opinions. These materials outline the terms of senior notes and the covenants that apply to The Cigna Group’s indebtedness.
Using this page, you can access real-time updates from EDGAR alongside AI-powered summaries that explain the key points of lengthy filings in plain language. AI analysis can help you quickly identify segment performance drivers in 10-Qs and 10-Ks, interpret the implications of new debt issuances, and understand governance or committee changes disclosed in 8-Ks. You can also review any Form 4 insider transaction reports, when available, to see how directors and executives are trading CI shares.
For investors, analysts, and researchers, The Cigna Group’s SEC filings provide a structured record of its financial condition, strategic initiatives, risk disclosures, and corporate governance framework, and this page brings those documents together with tools to make them easier to interpret.
The Cigna Group director reports a routine deferred compensation transaction. On 11/28/2025, the director converted part of a cash retainer into 108.1939 phantom stock units under Cigna’s Deferred Compensation Plan of 2005 for Directors. Each phantom stock unit is the economic equivalent of one share of The Cigna Group’s common stock and will be settled in cash rather than stock.
After this transaction, the director beneficially owns 1,690.8366 phantom stock units, which includes 8.0936 units acquired through the plan’s dividend reinvestment feature. This filing reflects compensation deferral choices rather than an open‑market trade in Cigna common shares.
The Cigna Group reported that its Board of Directors approved changes to the Board’s committee structure on October 22, 2025, with an effective date of January 1, 2026. The Board undertook a comprehensive review to ensure committee responsibilities align with the company’s strategic priorities, remain balanced, and allow the full Board to spend more time on significant matters.
The changes include adjustments to the responsibilities of the Compliance Committee and updates to the oversight of technology at the Board level. The People Resources Committee’s responsibilities remain without material changes. Detailed descriptions of each committee’s responsibilities are available in their charters on the company’s website.
FMR LLC and Abigail P. Johnson filed an amended Schedule 13G reporting beneficial ownership in The Cigna Group (CI) as of September 30, 2025. They disclose 10,665,555.96 shares of common stock, representing 4.0% of the class.
FMR reports sole voting power over 7,258,548.81 shares and sole dispositive power over 10,665,555.96 shares, with no shared voting or dispositive power. Johnson reports sole dispositive power over 10,665,555.96 shares. The certification states the securities were acquired and are held in the ordinary course of business and not to change or influence control.
The Cigna Group (CI) Chairman & CEO and director reported an open‑market purchase of 4,134 shares on 11/03/2025 at a weighted average price of $241.8762, with individual prices ranging from $241.876 to $241.97.
Following the transaction, beneficial ownership stands at 21,356 shares held directly; 157,935 shares held indirectly by trust; 440,798 shares held indirectly by a grantor retained annuity trust; and 1,782.7866 shares held indirectly via the 401(k) plan.
The Cigna Group reported stronger Q3 2025 results. Total revenues were $69,748 million, up from $63,694 million a year ago, driven by pharmacy revenues of $56,054 million. Premiums were $9,081 million. Income from operations was $2,578 million, roughly flat year over year.
Shareholders’ net income rose to $1,868 million and diluted EPS increased to $6.98 from $2.63, aided by lower medical costs ($7,842 million vs. $9,527 million) and net investment gains ($26 million vs. a loss of $921 million). The company recorded a gain on sale of businesses and reported shareholders’ comprehensive income of $1,885 million. Cash and cash equivalents were $6,025 million and long‑term debt was $30,947 million.
Cigna completed the sale of its Medicare-related businesses to HCSC, with the purchase price increased to $4.9 billion. The company recognized a Q3 pre-tax gain of $38 million and an after-tax gain of $241 million. It received approximately $4.2 billion in cash at closing and expects about $0.6 billion in Q4 2025. In September, Cigna issued $4.5 billion of senior notes and repaid a $2.0 billion term loan used to fund its investment in Shields Health Solutions. A quarterly dividend of $1.51 per share was declared for payment on December 18, 2025.
The Cigna Group furnished an update on quarterly performance. The company issued a press release announcing results for the three months ended September 30, 2025, and made it available as Exhibit 99.1.
The information was furnished, not filed, under the Securities Exchange Act of 1934. Common stock trades on the NYSE under the symbol CI. No additional financial details are included in this excerpt.
The Cigna Group announced that Retired Major General Elder Granger, M.D., will retire from its Board of Directors effective December 31, 2025.
The company said his retirement is consistent with the Board’s retirement age policy and is not the result of any disagreement with the Company. Dr. Granger informed the Board on October 15, 2025.
Brian C. Evanko, President and Chief Operating Officer, reported option exercises and open-market sales of Common Stock of Cigna Group (CI) under a Rule 10b5-1 plan. On
The transactions were effected under a 10b5-1 trading plan adopted on
Cigna Group (CI) filed a Form 144 disclosing a proposed sale of 5,368 common shares through Fidelity Brokerage Services LLC on 10/03/2025. The filing lists an aggregate market value of $1,610,400 and 266,928,075 shares outstanding for the issuer. The shares were acquired under an option granted on 03/01/2016 and are shown as acquired on 10/03/2025, with payment noted as cash. The filer certifies no undisclosed material adverse information and indicates no securities sold in the prior three months.
Koka Durga Prasad, Executive Vice President and Global CIO of Cigna Group (CI), filed an initial Form 3 reporting ownership after a qualifying event on 09/08/2025. The filing shows 4,324 shares of common stock held directly and five employee stock option grants covering 4,610 underlying shares (638, 634, 842, 1,137, 1,359) with exercise prices from $218.2525 to $336.475 and various exercisable/expiration dates through 2035. The form was signed by Elise Ryan, attorney-in-fact, on 09/17/2025.
FAQ
What is the current stock price of Cigna Group (CI)?
What is the market cap of Cigna Group (CI)?
